期刊文献+

Vascular restoration therapy and bioresorbable vascular scaffold 被引量:10

原文传递
导出
摘要 This article describes the evolution of minimally invasive intervention technologies for vascular restoration therapy from early-stage balloon angioplasty in 1970s,metallic bare metal stent and metallic drug-eluting stent technologies in 1990s and 2000s,to bioresorbable vascular scaffold(BVS)technology in large-scale development in recent years.The history,the current stage,the challenges and the future of BVS development are discussed in detail as the best available approach for vascular restoration therapy.The criteria of materials selection,design and processing principles of BVS,and the corresponding clinical trial results are also summarized in this article.
出处 《Regenerative Biomaterials》 SCIE 2014年第1期49-55,共7页 再生生物材料(英文版)
  • 相关文献

参考文献2

二级参考文献21

  • 1Moses JW, Leon MB, Popma J J, Fitzgerald P J, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-1323.
  • 2Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
  • 3Erne P, Schier M, Resink TJ. The road to Ioloabsorbal01e stents: reaching clinical reality? Cardiovasc Intervent Radiol 2006; 29: 11-16.
  • 4Wentzel J J, Whelan DM, van der Giessan WJ, van Beusekom HM, Andhyiswara I, Serruys PW, et al. Coronary stent implantation changes 3-D vessel geometry and 3-D shear stress distribution. J Biomech 2000; 33: 1287-1295.
  • 5Gy6ngy6si M, Yang P, Khorsand A, Glogar D. Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. J Am Coll Cardiol 2000; 35: 1580-1589.
  • 6Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897-910.
  • 7ColomboA, Karvouni E. Biodegradable stents: "fulfilling the mission and stepping away". Circulation 2000; 102: 371-373.
  • 8Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, et al. A bioabsorbable everolimus-eluting coronarystent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008; 371: 899-907.
  • 9Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 2007; 69:128-131.
  • 10Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010; 122:2301-2312.

共引文献51

同被引文献10

引证文献10

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部